Infinitum Asset Management LLC Takes $1.22 Million Position in Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB)

Infinitum Asset Management LLC purchased a new stake in shares of Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 155,529 shares of the company's stock, valued at approximately $1,218,000. Y-mAbs Therapeutics accounts for approximately 0.6% of Infinitum Asset Management LLC's investment portfolio, making the stock its 16th biggest holding. Infinitum Asset Management LLC owned 0.35% of Y-mAbs Therapeutics as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. JPMorgan Chase & Co. grew its position in Y-mAbs Therapeutics by 10.4% during the third quarter. JPMorgan Chase & Co. now owns 30,335 shares of the company's stock valued at $399,000 after buying an additional 2,854 shares during the period. SG Americas Securities LLC grew its position in shares of Y-mAbs Therapeutics by 30.7% during the 4th quarter. SG Americas Securities LLC now owns 17,729 shares of the company's stock valued at $139,000 after acquiring an additional 4,163 shares during the period. Principal Financial Group Inc. increased its stake in shares of Y-mAbs Therapeutics by 9.4% in the 4th quarter. Principal Financial Group Inc. now owns 22,197 shares of the company's stock worth $174,000 after purchasing an additional 1,903 shares in the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Y-mAbs Therapeutics by 1.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 284,540 shares of the company's stock valued at $2,228,000 after purchasing an additional 4,963 shares during the period. Finally, AlphaQuest LLC increased its position in Y-mAbs Therapeutics by 6,911.6% in the fourth quarter. AlphaQuest LLC now owns 27,135 shares of the company's stock worth $212,000 after buying an additional 26,748 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on the company. Bank of America cut Y-mAbs Therapeutics from a "neutral" rating to an "underperform" rating and set a $3.00 price objective on the stock. in a research report on Tuesday, April 22nd. HC Wainwright decreased their price objective on shares of Y-mAbs Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Morgan Stanley cut their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an "underweight" rating for the company in a research note on Wednesday, March 5th. Wedbush restated an "outperform" rating and issued a $18.00 price objective (down from $21.00) on shares of Y-mAbs Therapeutics in a research report on Wednesday. Finally, Truist Financial cut their target price on Y-mAbs Therapeutics from $18.00 to $14.00 and set a "buy" rating for the company in a research report on Wednesday, May 14th. Two research analysts have rated the stock with a sell rating, seven have assigned a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $15.60.

Insider Buying and Selling

In related news, insider Thomas Gad sold 10,810 shares of the stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $5.23, for a total value of $56,536.30. Following the sale, the insider now directly owns 202,721 shares of the company's stock, valued at $1,060,230.83. This represents a 5.06% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 22.50% of the stock is owned by corporate insiders.

Y-mAbs Therapeutics Price Performance

Shares of NASDAQ YMAB traded up $0.13 during mid-day trading on Thursday, hitting $4.75. 302,142 shares of the company's stock traded hands, compared to its average volume of 312,017. The company's 50-day moving average is $4.38 and its two-hundred day moving average is $6.51. Y-mAbs Therapeutics, Inc. has a 1 year low of $3.55 and a 1 year high of $16.11. The company has a market capitalization of $215.10 million, a P/E ratio of -8.80 and a beta of 0.53.

Y-mAbs Therapeutics (NASDAQ:YMAB - Get Free Report) last announced its earnings results on Tuesday, May 13th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.22) by $0.10. Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The firm had revenue of $20.90 million during the quarter, compared to analysts' expectations of $19.97 million. Equities analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current fiscal year.

Y-mAbs Therapeutics Company Profile

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.